Sirius Therapeutics
Sirius Therapeutics develops RNA interference (RNAi) therapeutics, focusing on small interfering RNA (siRNA) molecules for treating cardiovascular diseases. The company’s pipeline includes SRSD107, targeting coagulation factor XI for thromboembolic disorders, and SRSD101, aimed at treating dyslipidemia. Sirius Therapeutics is also developing SRSD216 for hyperlipoproteinemia(a), a lipid disorder related to atherosclerotic cardiovascular disease.
Domain
siriusrna.com
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$50.0M
Founded
2020
Tech Stack (5 technologies)
Frequently Asked Questions
What technologies does Sirius Therapeutics use?+
Sirius Therapeutics uses 5 technologies including Swiper, Baidu Analytics (百度统计), jQuery.
What industry is Sirius Therapeutics in?+
Sirius Therapeutics operates in the Biotechnology industry.
Where is Sirius Therapeutics based?+
Sirius Therapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026